Patents Assigned to ICOS
  • Derivatives of 2,3,6,7,12,12a-hexahydropyrazino-[1?,2?:1,6]pyrido[3,4b]-indole-1,4-dione
    Patent number: 6872721
    Abstract: Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: March 29, 2005
    Assignee: Lilly ICOS LLC
    Inventors: Mark W. Orme, Jason Scott Sawyer, Alain Claude-Marie Daugan
  • Condensed pyridoindole derivatives
    Patent number: 6858620
    Abstract: Compounds of general structural formula (I), and use of the compounds or salts or solvates thereof as therapeutic agents, are disclosed
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: February 22, 2005
    Assignee: Lilly ICOS, LLC
    Inventors: Mark W. Orme, Jason Scott Sawyer, Alain Claude-Marie Daugan, Romain Luc Marie Gosmini, Lisa M. Schultze
  • Condensed pyridoindole derivatives
    Patent number: 6838456
    Abstract: Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: January 4, 2005
    Assignee: Lilly ICOS LLC
    Inventors: Mark W. Orme, Jason Scott Sawyer, Alain Claude-Marie Daugan, Françoise Gellibert, Romain Luc Marie Gosmini
  • Cyclic GMP-specific phosphodiesterase inhibitors
    Patent number: 6825197
    Abstract: Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: November 30, 2004
    Assignee: Lilly ICOS LLC
    Inventors: Mark W. Orme, Jason Scott Sawyer
  • Beta-carboline drug products
    Patent number: 6821975
    Abstract: A compound of structural formula (I), and pharmaceutically acceptable salts and solvates thereof, wherein the compound is in free drug particulate form, is disclosed.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: November 23, 2004
    Assignee: Lilly ICOS LLC
    Inventors: Neil R. Anderson, Kerry J. Hartauer, Martha A. Kral, Gregory A. Stephenson
  • I-CAM related protein
    Patent number: 6818743
    Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated “ICAM-R”) and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Antibodies substances specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding reactions involving ICAM-R.
    Type: Grant
    Filed: September 28, 1994
    Date of Patent: November 16, 2004
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Rosemay Vazeux
  • ATR-2 cell cycle checkpoint
    Patent number: 6815532
    Abstract: Polynucleotides encoding novel Atr-2 cell cycle checkpoint polypeptides are disclosed, along with expression constructs comprising the polynucleotides, host cells transformed with the expression constructs, methods to make the Atr-2 polypeptides using the host cells, Atr-2 polypeptides, and binding partners of the Atr-2 polypeptides.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: November 9, 2004
    Assignee: ICOS Corporation
    Inventors: Kate Loughney, Kathleen S. Keegan
  • Inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: 6800620
    Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K&dgr;) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K&dgr; plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K&dgr;, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K&dgr; activity, including compounds that selectively inhibit PI3K&dgr; activity. Methods of using PI3K&dgr; inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K&dgr; inhibitory compounds to inhibit PI3K&dgr;-mediated processes in vitro and in vivo.
    Type: Grant
    Filed: January 6, 2003
    Date of Patent: October 5, 2004
    Assignee: ICOS
    Inventors: Chanchal Sadhu, Ken Dick, Jennifer Treiberg, C. Gregory Sowell, Edward A. Kesicki, Amy Oliver
  • Polynucleotides encoding macrophage derived chemokine
    Patent number: 6790947
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C—C chemokine designated MDC. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 14, 2004
    Assignee: ICOS Corporation
    Inventors: Ronald Godiska, Patrick W. Gray
  • Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
    Patent number: 6787542
    Abstract: The present invention relates to novel heterocyclyl-containing diaryl sulfide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: September 7, 2004
    Assignee: ICOS Corporation
    Inventors: Gary T. Wang, Sheldon Wang, Robert Gentles
  • Tetracyclic derivatives, process of preparation and use
    Patent number: 6784179
    Abstract: A compound of formula (I) and salts and solvates thereof, in which: R0 represents hydrogen, halogen or C1-6 alkyl; R1 represents hydrogen, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, halo C1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroaryl C1-3alkyl; R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring  attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: August 31, 2004
    Assignee: ICOS Corporation
    Inventor: Alain Claude-Marie Daugan
  • Measuring positions of coplanarity of contract elements of an electronic component with a flat illumination and two cameras
    Patent number: 6778282
    Abstract: A method and an apparatus for measuring respective positions of a set of contact elements of an electronic component, wherein the contact elements are illuminated with a light source producing a light with an incident angle of at the most 20° and wherein a first respectively a second image is recorded of said elements by means of a first respectively a second camera which are set up over a triangulation angle with respect to each other.
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: August 17, 2004
    Assignee: ICOS Vision Systems N.V.
    Inventors: Carl Smets, Karel Van Gils, Maarten Van Der Burgt
  • Methods of inhibiting inflammatory processes and alleviating symptoms associated with multiple sclerosis
    Patent number: 6737059
    Abstract: Disclosed are methods for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory disease processes associated with the multiple sclerosis disease, by adminstering to a patient a phamaceutically effective amount of mAb 23F2G or an antibody that competes with mAb 23F2G for binding to LFA-1.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: May 18, 2004
    Assignees: Board of Regents of the University Washington, ICOS Corporation
    Inventor: Lynn M. Rose
  • Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
    Patent number: 6737513
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C-C chemokine designated Macrophage Derived Chemokine (MDC), and polypeptide analogs thereof Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing.
    Type: Grant
    Filed: April 28, 1998
    Date of Patent: May 18, 2004
    Assignee: ICOS Corporation
    Inventors: Patrick W. Gray, David H. Chantry, Michael C. Deeley
  • Parp inhibitors
    Publication number: 20040087588
    Abstract: The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same.
    Type: Application
    Filed: August 15, 2002
    Publication date: May 6, 2004
    Applicant: ICOS Corporation
    Inventors: Graham Beaton, Wilna J. Moree, Jaimie K. Rueter, Russell S. Dahl, David L. McElligott, Phyllis Goldman, Anthony J. Demaggio, Erik Christenson, Dan Herendeen, Kerry W. Fowler, Danwen Huang, Jaimie A. Bertino, Lisa H. Bourdon, David J. Fairfax, Qin Jiang, Helge A. Reisch, Ren Hua Song, Pavel E. Zhichkin
  • CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS
    Publication number: 20040023945
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: May 17, 2002
    Publication date: February 5, 2004
    Applicant: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6680336
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: January 20, 2004
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Laurence E. Burgess, Stephen T. Schlachter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20030236412
    Abstract: Pyrazole compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: April 18, 2003
    Publication date: December 25, 2003
    Applicant: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Carmen C. Hertel, Amy Oliver
  • Inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: 6667300
    Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K&dgr;) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K&dgr; plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K&dgr;, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K&dgr; activity, including compounds that selectively inhibit PI3K&dgr; activity. Methods of using PI3K&dgr; inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K&dgr; inhibitory compounds to inhibit PI3K&dgr;-mediated processes in vitro and in vivo.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: December 23, 2003
    Assignee: ICOS Corporation
    Inventors: Chanchal Sadhu, Ken Dick, Jennifer Treiberg, C. Gregory Sowell, Edward A. Kesicki, Amy Oliver
  • Inhibitors of human phosphatidylinositol 3-kinase delta
    Publication number: 20030195211
    Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K&dgr;) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K&dgr; plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K&dgr;, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K&dgr; activity, including compounds that selectively inhibit PI3K&dgr; activity. Methods of using PI3K&dgr; inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K&dgr; inhibitory compounds to inhibit PI3K&dgr;-mediated processes in vitro and in vivo.
    Type: Application
    Filed: January 6, 2003
    Publication date: October 16, 2003
    Applicant: ICOS Corporation
    Inventors: Chanchal Sadhu, Ken Dick, Jennifer Treiberg, C. Gregory Sowell, Edward A. Kesicki, Amy Oliver